Cargando…

Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial

INTRODUCTION: Using data from the VERTIS CV trial (NCT01986881), the impact of ertugliflozin in patients with nonalbuminuric diabetic kidney disease (DKD-non-Alb) was assessed. METHODS: Patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) were randomized t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cherney, David Z.I., Dagogo-Jack, Samuel, Cosentino, Francesco, Pratley, Richard E., Frederich, Robert, Maldonado, Mario, Liu, Chih-Chin, Cannon, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366295/ https://www.ncbi.nlm.nih.gov/pubmed/35967112 http://dx.doi.org/10.1016/j.ekir.2022.05.007

Ejemplares similares

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022)

Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
por: Cherney, David Z.I., et al.
Publicado: (2022)

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2022)

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
por: Cherney, David Z. I., et al.
Publicado: (2021)

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
por: Dagogo-Jack, Samuel, et al.
Publicado: (2023)

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
por: Dagogo-Jack, Samuel, et al.
Publicado: (2021)

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2020)

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
por: Wojeck, Brian S., et al.
Publicado: (2022)

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
por: Segar, Matthew W., et al.
Publicado: (2022)

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
por: Budoff, Matthew J., et al.
Publicado: (2021)

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]
por: Cherney, David Z. I., et al.
Publicado: (2022)

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
por: Grunberger, George, et al.
Publicado: (2017)

Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials
por: Cherney, David Z. I., et al.
Publicado: (2021)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
por: Miller, Sam, et al.
Publicado: (2018)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2017)

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
por: Cherney, David Z. I., et al.
Publicado: (2020)

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
por: Hollander, Priscilla, et al.
Publicado: (2017)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
por: Liu, Hongyan, et al.
Publicado: (2021)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes
por: Korbut, Anton I, et al.
Publicado: (2019)

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
por: Aronson, Ronnie, et al.
Publicado: (2018)

Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria
por: D’Marco, Luis, et al.
Publicado: (2022)

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
por: Gallo, Silvina, et al.
Publicado: (2019)

Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-Albuminuric Diabetic Kidney Disease
por: Klimontov, Vadim V., et al.
Publicado: (2020)

CVD risk in non-albuminuric chronic kidney disease in hypertensive, non-diabetic subjects: A post-hoc analysis from SPRINT
por: Sheng, Chang-Sheng, et al.
Publicado: (2022)

Non-albuminuric chronic kidney disease in diabetes: A different approach?
por: Borg, Rikke, et al.
Publicado: (2022)

On Albuminuric Retinitis
por: Robertson, D. Argyll
Publicado: (1871)

A role for NPY-NPY2R signaling in albuminuric kidney disease
por: Lay, Abigail C., et al.
Publicado: (2020)

Prognosis in Albuminuric Retinitis
Publicado: (1901)

Albuminuric Retinitis of Pregnancy
Publicado: (1883)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
por: McGuire, Darren K., et al.
Publicado: (2020)

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease
por: Kinguchi, Sho, et al.
Publicado: (2021)

AKI-to-CKD transition is a potential mechanism for non-albuminuric diabetic kidney disease
por: Lee, Kyung, et al.
Publicado: (2022)

Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
por: Scilletta, Sabrina, et al.
Publicado: (2023)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Overview of Ertugliflozin
por: Nguyen, Vivianne K., et al.
Publicado: (2019)

A Case of Albuminuric Eclampsia
por: Ullman, G. L.
Publicado: (1875)

Cannot write session to /tmp/vufind_sessions/sess_3cvp31p42irkbbtjc7p1i1v835